Granahan Investment Management LLC Purchases 77,841 Shares of Phreesia, Inc. $PHR

Granahan Investment Management LLC boosted its position in Phreesia, Inc. (NYSE:PHR) by 6.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 1,380,626 shares of the company’s stock after purchasing an additional 77,841 shares during the period. Phreesia comprises approximately 1.3% of Granahan Investment Management LLC’s investment portfolio, making the stock its 23rd largest position. Granahan Investment Management LLC’s holdings in Phreesia were worth $32,472,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after acquiring an additional 16,309 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock valued at $4,090,000 after purchasing an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after purchasing an additional 2,158 shares during the period. NewEdge Advisors LLC raised its position in Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after purchasing an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Phreesia by 0.4% in the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after purchasing an additional 2,402 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors.

Phreesia Trading Down 0.2%

Shares of PHR opened at $10.98 on Monday. The firm has a fifty day simple moving average of $13.70 and a two-hundred day simple moving average of $19.06. Phreesia, Inc. has a twelve month low of $10.77 and a twelve month high of $32.76. The stock has a market capitalization of $661.68 million, a P/E ratio of -109.74 and a beta of 0.67. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01.

Insider Activity

In other news, SVP Amy Beth Vanduyn sold 2,602 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $44,260.02. Following the completion of the sale, the senior vice president directly owned 160,238 shares in the company, valued at approximately $2,725,648.38. This represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Evan Roberts sold 6,317 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $107,452.17. Following the completion of the sale, the insider directly owned 834,632 shares in the company, valued at $14,197,090.32. The trade was a 0.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 60,766 shares of company stock valued at $1,013,817. 5.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Phreesia in a research report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 price target for the company. Wells Fargo & Company started coverage on Phreesia in a research note on Thursday, January 8th. They issued an “overweight” rating and a $30.00 target price for the company. DA Davidson dropped their target price on Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Barclays reduced their price target on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 16th. Finally, Mizuho set a $22.00 price target on Phreesia in a research note on Wednesday, February 4th. Seventeen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.12.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.